Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warns Generics Firms About January QbD Deadline for ANDAs

This article was originally published in The Gold Sheet

Executive Summary

Come January, if there is no quality target product profile (QTPP) in an abbreviated new drug application (ANDA), FDA might not file it, agency officials told a Generic Pharmaceutical Association workshop. Even though quality by design (QbD) remains optional for brand drugs, it will be expected for generics, said Office of Generic Drugs representatives who went on to outline pending question-based-review (QbR) revisions designed to elicit QbD information.


Related Content

Despite Widespread Adoption, Questions Persist on Benefits of QbD
FDA Proposes QbR for New Drugs to Level the Playing Field for CMC Reviews
Generic Industry Has Made Progress Implementing QbD
Generics in Brief
FDA Presses Generics Firms to Speed Adoption of QbD, While Questions on Use of Prior Knowledge Persist
In Brief
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
FDA Officials Urge Generic Drug Industry to Adopt QbD to Improve Submissions





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts